Clinical Trials
5 trialsNCT00667862 2021-06-21
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT00493766 2020-12-19
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Novartis
Phase 1 Terminated
NCT00663832 2020-12-19
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
Novartis
Phase 1 Completed
NCT00670553 2017-05-17
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
Novartis
Phase 1 Completed
NCT00419536 2010-04-08
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
Novartis
Phase 1 Terminated